Isorhapontigenin protects against doxorubicin-induced cardiotoxicity
Acta Pharmaceutica Sinica B
; (6): 680-693, 2021.
Article
en En
| WPRIM
| ID: wpr-881162
Biblioteca responsable:
WPRO
ABSTRACT
As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of YAP1 in Dox-induced cardiomyopathy has not been reported. In this study, the expression of YAP1 was reduced in clinical human failing hearts with dilated cardiomyopathy and Dox-induced
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Acta Pharmaceutica Sinica B
Año:
2021
Tipo del documento:
Article